Vivan Therapeutics wins approval for Abu Dhabi TuMatch cancer study

Vivan Therapeutics has cleared regulatory approvals to start a clinical registration study of its AI-based TuMatch software at Burjeel Cancer Institute in Abu Dhabi. The colorectal cancer study will generate UAE clinical and health-economics data that could support reimbursement, broader adoption and future CE mark and FDA filings.

Why it matters: - The study could become an early UAE evidence base for AI-enabled oncology decision support in colorectal cancer. - The data are intended to inform reimbursement discussions and shape how precision oncology software is adopted across the UAE health system. - The approval is one of the first regulatory clearances in Abu Dhabi for this class of oncology software.

What happened: - Vivan Therapeutics received all regulatory approvals to begin its clinical registration study of TuMatch at Burjeel Cancer Institute, Burjeel Medical City, Abu Dhabi. - The company is part of Hub71, Abu Dhabi's global tech ecosystem. - The prospective study will evaluate TuMatch in patients with colorectal cancer. - Prof. Humaid Al Shamsi will lead the study at the Abu Dhabi site. - The study will enroll at least 10 patients.

The details: - TuMatch analyzes a patient's tumor genomic profile against Vivan's proprietary drug-response dataset. - The dataset was generated using an in vivo Drosophila "avatar" screening platform developed with Mount Sinai Medical Center and published clinical evidence. - The software returns a ranked set of therapeutic options for oncologists. - The tool is aimed at patients who have exhausted standard-of-care regimens or are unlikely to benefit from them. - The study will collect clinical outcomes, health economics data and value-based care data. - Vivan said the evidence is meant to support future reimbursement discussions with payers. - Colorectal cancer is among the most commonly diagnosed cancers in the UAE. - The disease often presents at a younger age or later stage than in Western populations.

Between the lines: - The Abu Dhabi study gives Vivan a live clinical setting to validate TuMatch beyond development-stage testing. - The program also positions Abu Dhabi as a launch point for regulated AI healthcare deployment, not just startup formation. - Vivan said data from the UAE and future studies will support CE mark and FDA submissions for TuMatch. - The company's broader clinical program includes a planned multicentre study in pancreatic and other GI cancers with sites in Europe and the GCC. - Laura Towart, Vivan's founder and CEO, said the approval moves TuMatch from a validated platform to a tool used in live clinical decision-making.

What's next: - The study will begin patient enrollment at Burjeel Cancer Institute in Abu Dhabi. - Vivan will use the study data to build its regulatory and reimbursement case for TuMatch. - The company expects evidence from the UAE and other sites to feed into future international filings. - Vivan established its regional entity in Abu Dhabi Global Market in 2025 and operates across the UK, USA, UAE and China.

The bottom line: - Vivan is moving TuMatch from software validation into real-world oncology use, with Abu Dhabi serving as the first proving ground for both clinical and commercial evidence.